These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 26549785

  • 1. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study.
    Santus P, Radovanovic D, Di Marco F, Raccanelli R, Valenti V, Centanni S.
    Pulm Pharmacol Ther; 2015 Dec; 35():42-9. PubMed ID: 26549785
    [Abstract] [Full Text] [Related]

  • 2. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.
    Beeh KM, Watz H, Puente-Maestu L, de Teresa L, Jarreta D, Caracta C, Garcia Gil E, Magnussen H.
    BMC Pulm Med; 2014 Dec 23; 14():209. PubMed ID: 25539654
    [Abstract] [Full Text] [Related]

  • 3. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
    Watz H, Mailänder C, May C, Baier M, Kirsten AM.
    Pulm Pharmacol Ther; 2017 Feb 23; 42():13-20. PubMed ID: 27940287
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.
    Karabis A, Lindner L, Mocarski M, Huisman E, Greening A.
    Int J Chron Obstruct Pulmon Dis; 2013 Feb 23; 8():405-23. PubMed ID: 24043936
    [Abstract] [Full Text] [Related]

  • 5. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, Hiltl S, Bauersachs J, Welte T.
    Lancet Respir Med; 2018 May 23; 6(5):368-378. PubMed ID: 29477448
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falqués M, Caracta CF, Garcia Gil E.
    Chest; 2012 Mar 23; 141(3):745-752. PubMed ID: 21903737
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
    Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A, Matera MG, Cazzola M.
    Eur J Pharmacol; 2015 Aug 15; 761():383-90. PubMed ID: 25952728
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.
    Lee SH, Lee J, Yoo KH, Uh ST, Park MJ, Lee SY, Kim JY, Kim DK, Kim SJ, Lee KH, Yoo CG.
    Respirology; 2015 Nov 15; 20(8):1222-8. PubMed ID: 26370136
    [Abstract] [Full Text] [Related]

  • 9. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, Banerji D.
    Respir Med; 2014 Apr 15; 108(4):584-92. PubMed ID: 24534204
    [Abstract] [Full Text] [Related]

  • 10. Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
    Manoharan A, Morrison AE, Lipworth BJ.
    Lung; 2016 Apr 15; 194(2):259-66. PubMed ID: 26758884
    [Abstract] [Full Text] [Related]

  • 11. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.
    Singh D, Magnussen H, Kirsten A, Mindt S, Caracta C, Seoane B, Jarreta D, Garcia Gil E.
    Pulm Pharmacol Ther; 2012 Jun 15; 25(3):248-53. PubMed ID: 22497752
    [Abstract] [Full Text] [Related]

  • 12. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
    Beier J, Mroz R, Kirsten AM, Chuecos F, Gil EG.
    Int J Chron Obstruct Pulmon Dis; 2017 Jun 15; 12():1731-1740. PubMed ID: 28652725
    [Abstract] [Full Text] [Related]

  • 13. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.
    Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E.
    Int J Chron Obstruct Pulmon Dis; 2017 Jun 15; 12():2545-2558. PubMed ID: 28883722
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
    LaForce C, Feldman G, Spangenthal S, Eckert JH, Henley M, Patalano F, D'Andrea P.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun 15; 11():1233-43. PubMed ID: 27354782
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
    Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E.
    Eur Respir J; 2012 Oct 15; 40(4):830-6. PubMed ID: 22441743
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.
    Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, Gil EG.
    COPD; 2013 Aug 15; 10(4):511-22. PubMed ID: 23819698
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
    Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF, ACCORD I study investigators.
    COPD; 2012 Apr 15; 9(2):90-101. PubMed ID: 22320148
    [Abstract] [Full Text] [Related]

  • 18. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
    Watz H, Mailänder C, Baier M, Kirsten A.
    BMC Pulm Med; 2016 Jun 14; 16(1):95. PubMed ID: 27301417
    [Abstract] [Full Text] [Related]

  • 19. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
    Riario-Sforza GG, Ridolo E, Riario-Sforza E, Incorvaia C.
    Expert Rev Respir Med; 2015 Feb 14; 9(1):23-33. PubMed ID: 25547422
    [Abstract] [Full Text] [Related]

  • 20. A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
    Arievich H, Overend T, Renard D, Gibbs M, Alagappan V, Looby M, Banerji D.
    BMC Pulm Med; 2012 Dec 08; 12():74. PubMed ID: 23217058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.